Trailblazing a Next Generation Treatment for Solid Tumors
Who We Are
CorriXR Therapeutics is an oncology-focused biotherapeutics development company with a ground-breaking gene editing platform technology.
CorriXR Therapeutics is the inaugural biotech spin-out of ChristianaCare, a large healthcare system, and the Gene Editing Institute, which has been embedded in ChristianaCare’s Helen F. Graham Cancer Center & Research Institute since 2015.
What We’re Doing
CorriXR is developing a new paradigm for treatment of solid tumors with a unique CRISPR/Cas biomolecular tool that knocks out the gene for the master transcriptional regulator NRF2.
Our preclinically validated lead program CXR101, uses knock out of NRF2 to alter the tumor microenvironment and disable drug resistance pathways in squamous cell carcinoma of the head and neck (HNSCC). Our delivery system is a proven lipid nanoparticle approach that when combined with direct intratumoral injection minimizes off-target effects.
Our proprietary in vivo gene editing platform has broad applicability for 30+ squamous cell carcinomas and enhances tumor cell stress response to all standard of care treatments.
Meet Our Team Members
Get to know our leadership team.